comprehensive -WSS

comprehensive

author：fashion 2025-09-06 02:28:47 - browse：49

A glass office building of MassMutual with its sign on the top left — insurance coverage from STAT — Adobe

One of the country’s biggest life insurers is venturing into genetic testing, an area that’s historically been a minefield for that industry, in a purported effort to keep its members alive longer.

MassMutual announced Tuesday that it’s offering many of its 4.2 million policyholders free genetic risk assessments for eight common diseases, like heart disease, type 2 diabetes, and breast cancer. The Springfield, Mass.-based insurer hopes that when people learn they carry a genetic predisposition, they’ll take action to lower their risk through diet, exercise, and getting regular screenings.

Viewed one way, it’s a win-win: The longer its members live, the longer MassMutual can collect and invest their premiums without paying out.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Morphosys mixed study results for blood cancer drug

WSS

Childhood cancer progress stalls for Black, Hispanic kids: Report

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

The most pressing bird flu mysteries scientists want answered

FDA's Woodcock to retire early next year

Finland to offer bird flu vaccine to select groups of people, a possible global first

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

entertainment

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

explore

Medical leaders decry Supreme Court decision on affirmative action

Data don't support strong claims for Covid

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Take antibiotics after sex, CDC recommends for certain risk groups

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA approves Moderna’s RSV vaccine, its second licensed product

Hollywood unions extend contract negotiations for actors

Senators tussle over abortion against the backdrop of a presidential campaign

Jerome Adams on the need for new antivirals for Covid

Data don't support strong claims for Covid

focus

Sutter Health’s antitrust win overturned by appeals court

In key trial, Verve's treatment lowers cholesterol levels in patients

Childhood cancer progress stalls for Black, Hispanic kids: Report

U.K. considers world's first use of meningitis vaccine to address gonorrhea

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

focus

Wikipedia

focus

focus